Vaskulitiden des zentralen Nervensystems

A. Steinbrecher

doi:10.1055/s-0042-106079

Aktuelle Rheumatologie, Table of Contents

Aktuelle Rheumatologie 2016; 41(03): 200-213
DOI: 10.1055/s-0042-106079

Vaskulitiden des zentralen Nervensystems

Vasculitis of the Central Nervous System

A. Steinbrecher

¹Neurologie, HELIOS Klinikum Erfurt, Erfurt

› Author Affiliations

Abstract

Zusammenfassung

Vaskulitiden des zentralen Nervensystems (ZNS) sind definiert durch entzündliche Veränderungen intrakranieller und gelegentlich spinaler Gefäße und kommen als zerebrale Manifestationen systemischer Vaskulitiden, als sekundäre Vaskulitis bei nicht vaskulitischer Grunderkrankung oder als isolierte ZNS-Angiitis (IAZNS) vor. Obwohl selten, müssen sie aufgrund der Vielfalt und fehlenden Spezifität klinischer und radiologischer Befunde sehr häufig differenzialdiagnostisch berücksichtigt werden. Bei Patienten mit subakuten Krankheitsbildern, multifokaler neurologischer Symptomatik, Kopfschmerzen, psychiatrischen Symptomen oder systemischer Entzündung sowie jungen Schlaganfallpatienten ohne typische Risikofaktoren bzw. mit rheumatologischen Begleiterkrankungen sollte an eine ZNS-Vaskulitis gedacht werden. Neben dem Nachweis der Vaskulitis selbst sind die Klärung der Ätiologie und insbesondere der Ausschluss von Infektionen besonders wichtig. Auch durch invasive diagnostische Maßnahmen wie die zerebrale Angiografie und die als diagnostischer Goldstandard geltende ZNS-Biopsie kann speziell die Diagnose einer IAZNS oft nur wahrscheinlich gemacht werden. Neben der Therapie etwaiger Grunderkrankungen werden zerebrale Vaskulitiden meist kombiniert mit Kortikosteroiden und Immunsuppressiva behandelt. Dabei sollten Schwere der Erkrankung und der Grad der diagnostischen Sicherheit berücksichtigt werden.

Abstract

Central nervous system (CNS) vasculitides are defined by inflammatory changes of intracranial and, occasionally, spinal vessel walls. They occur as cerebral manifestations of systemic vasculitides or can be a result of non-vasculitic diseases or present as isolated angiitis of the CNS. Although being rare diseases, they frequently have to be considered in the differential diagnosis due to the etiologically non-specific nature of clinical and radiological findings. A subacute presentation of multifocal neurological symptoms, headache, psychiatric symptoms or systemic inflammation, or the occurrence of stroke in patients of young age lacking a vascular risk profile or with known concomitant rheumatological diseases should raise the suspicion of CNS vasculitis. In addition to the confirmation of vasculitis, its etiology must be clarified, and – most importantly – infections have to be ruled out. In the case of isolated CNS angiitis, even invasive diagnostic measures such as cerebral angiography and CNS biopsy, which is the diagnostic gold standard, often do not lead to a definitive diagnosis. In addition to the treatment of any causative conditions, cerebral vasculitides are typically treated with a combination of corticosteroids and immunosuppressants. Instead of a uniform approach, disease severity and the degree of diagnostic certainty should be considered for the choice of treatment.

Schlüsselwörter

Vaskulitis - zentrales Nervensystem - Schlaganfall - rheumatische Erkrankungen - Kollagenosen

Key words

vasculitis - central nervous system - stroke - rheumatic diseases - connective tissue diseases

Full Text

References

Literatur
1 Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis rheum 2013; 65: 1-11
2 Hajj-Ali RA, Singhal AB, Benseler S et al. Primary angiitis of the CNS. Lancet Neurol 2011; 10: 561-572
3 Calabrese LH, Mallek JA. Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine 1988; 67: 20-39
4 Alrawi A, Trobe JD, Blaivas M et al. Brain biopsy in primary angiitis of the central nervous system. Neurology 1999; 53: 858-860
5 Chu CT, Gray L, Goldstein LB et al. Diagnosis of intracranial vasculitis: a multi-disciplinary approach. J Neuropathol Exp Neurol 1998; 57: 30-38
6 Duna GF, Calabrese LH. Limitations of invasive modalities in the diagnosis of primary angiitis of the central nervous system. J Rheumatol 1995; 22: 662-667
7 Cupps TR, Moore PM, Fauci AS. Isolated angiitis of the central nervous system. Prospective diagnostic and therapeutic experience. Am J Med 1983; 74: 97-105
8 Calabrese LH, Gragg LA, Furlan AJ. Benign angiopathy: a distinct subset of angiographically defined primary angiitis of the central nervous system. J Reumatol 1993; 20: 2046-2050
9 Kramer M, Berlit P. Reversible cerebral vasoconstriction syndrome vs. cerebral vasculitis? On the importance and difficulty of differentiating. Nervenarzt 2011; 82: 500 502, 504-505
10 de Boysson H, Zuber M, Naggara O et al. Primary angiitis of the central nervous system: description of the first fifty-two adults enrolled in the French cohort of patients with primary vasculitis of the central nervous system. Arthritis Rheum 2014; 66: 1315-1326
11 Geri G, Saadoun D, Guillevin R et al. Central nervous system angiitis: a series of 31 patients. Clin Rheumatol 2014; 33: 105-110
12 Kraemer M, Berlit P. Primary central nervous system vasculitis: clinical experiences with 21 new European cases. Rheumatol Int 2011; 31: 463-472
13 Salvarani C, Brown Jr. RD, Christianson T et al. An update of the Mayo Clinic cohort of patients with adult primary central nervous system vasculitis: description of 163 patients. Medicine 2015; 94: e738
14 Salvarani C, Brown Jr. RD, Calamia KT et al. Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol 2007; 62: 442-451
15 Twilt M, Benseler SM. The spectrum of CNS vasculitis in children and adults. Nat Rev Rheumatol 2012; 8: 97-107
16 Kuker W, Gaertner S, Nagele T et al. Vessel wall contrast enhancement: a diagnostic sign of cerebral vasculitis. Cerebrovasc Dis 2008; 26: 23-29
17 Mandell DM, Matouk CC, Farb RI et al. Vessel wall MRI to differentiate between reversible cerebral vasoconstriction syndrome and central nervous system vasculitis: preliminary results. Stroke 2012; 43: 860-862
18 Obusez EC, Hui F, Hajj-Ali RA et al. High-resolution MRI vessel wall imaging: spatial and temporal patterns of reversible cerebral vasoconstriction syndrome and central nervous system vasculitis. AJNR 2014; 35: 1527-1532
19 Pfefferkorn T, Linn J, Habs M et al. Black blood MRI in suspected large artery primary angiitis of the central nervous system. J Neuroimaging 2013; 23: 379-383
20 Zuber M. Isolated angiitis of the central nervous system. In: Caplan LR. (Hrsg.) Uncommon causes of stroke. Cambridge: Cambridge University Press; 2008: 1-8
21 Birnbaum J, Hellmann DB. Primary angiitis of the central nervous system. Arch Neurol 2009; 66: 704-709
22 Kadkhodayan Y, Alreshaid A, Moran CJ et al. Primary angiitis of the central nervous system at conventional angiography. Radiology 2004; 233: 878-882
23 Demaerel P, De Ruyter N, Maes F et al. Magnetic resonance angiography in suspected cerebral vasculitis. Eur Radiol 2004; 14: 1005-1012
24 Berlit P, Kraemer M AS et al. Leitlinie Zerebrale Vaskulitis. In: HC D, Weimar C, Berlit P. (Hrsg.) Leitlinien der Deutschen Gesellschaft für Neurologie. 5. Aufl. Stuttgart: Thieme; 2012: 406-427
25 Parisi JE, Moore PM. The role of biopsy in vasculitis of the central nervous system. Semin Neurol 1994; 14: 341-348
26 Sommerville RB, Noble JM, Vonsattel JP et al. Eosinophilic vasculitis in an isolated central nervous system distribution. JNNP 2007; 78: 85-88
27 Scolding NJ, Joseph F, Kirby PA et al. Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 2005; 128: 500-515
28 Molloy ES, Singhal AB, Calabrese LH. Tumour-like mass lesion: an under-recognised presentation of primary angiitis of the central nervous system. Ann Rheum Dis 2008; 67: 1732-1735
29 Berlit P, Kraemer M. Cerebral vasculitis in adults: what are the steps in order to establish the diagnosis? Red flags and pitfalls. Clin Exp Immunol 2014; 175: 419-424
30 Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med 2014; 371: 50-57
31 Ness T, Bley TA, Schmidt WA et al. The diagnosis and treatment of giant cell arteritis. Deutsches Ärzteblatt international 2013; 110: 376-385 quiz 386
32 Caselli RJ, Hunder GG. Neurologic complications of giant cell (temporal) arteritis. Semin Neurol 1994; 14: 349-353
33 Thielen KR, Wijdicks EF, Nichols DA. Giant cell (temporal) arteritis: involvement of the vertebral and internal carotid arteries. Mayo Clinic Proc 1998; 73: 444-446
34 Haas S, Jurgens T, Vatankhah B et al. Multiple ischemic vertebrobasilar lesions in temporal arteritis. Nervenarzt 2005; 76: 1527 1529-1531
35 Boettinger M, Sebastian S, Gamulescu MA et al. Bilateral vertebral artery occlusion with retrograde basilary flow in three cases of giant cell arteritis. BMJ case reports 2009;
36 Wilkinson IM, Russell RW. Arteries of the head and neck in giant cell arteritis. A pathological study to show the pattern of arterial involvement. Arch Neurol 1972; 27: 378-391
37 Aiello PD, Trautmann JC, McPhee TJ et al. Visual prognosis in giant cell arteritis. Ophthalmology 1993; 100: 550-555
38 Grossman C, Barshack I, Bornstein G et al. Is temporal artery biopsy essential in all cases of suspected giant cell arteritis?. Clin Exp Rheumatol 2015; 33: S-84-S-89
39 Patil P, Williams M, Maw WW et al. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol 2015; 33: S-103-S-106
40 Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68: 318-323
41 Polachek A, Pauzner R, Levartovsky D et al. The fine line between Takayasu arteritis and giant cell arteritis. Clin Rheumatol 2015; 34: 721-727
42 Gao S, Wang R. Takayasu arteritis presenting with massive cerebral ischemic infarction in a 35-year-old woman: a case report. J Med Case Rep 2013; 7: 179
43 Chatterjee S, Flamm SD, Tan CD et al. Clinical diagnosis and management of large vessel vasculitis: Takayasu arteritis. Curr Cardiol Rep 2014; 16: 499
44 Stagnaro C, Cioffi E, Talarico R et al. Systemic vasculitides: a critical digest of the most recent literature. Clin Exp Rheumatol 2015; 33: S-145-S-154
45 Kotter I, Henes JC, Wagner AD et al. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 2012; 30: S114-S129
46 Saadoun D, Lambert M, Mirault T et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation 2012; 125: 813-819
47 Adams HP. Cerebral vasculitis. In: Biller J, Ferro JM. (Hrsg.) Handb Clin Neurol, Neurologic Aspects of Systemic Disease Part I. Amsterdam: Elsevier B.V.; 2014: 475-494
48 Pagnoux C, Seror R, Henegar C et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 2010; 62: 616-626
49 Samson M, Puechal X, Devilliers H et al. Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors. Autoimmun Rev 2014; 13: 945-953
50 Guillevin L, Lhote F, Cohen P et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995; 38: 1638-1645
51 Guillevin L, Jarrousse B, Lok C et al. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 1991; 18: 567-574
52 Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 310-317
53 Zhang W, Zhou G, Shi Q et al. Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides. Clin Exp Rheumatol 2009; 27: S65-S69
54 Seror R, Mahr A, Ramanoelina J et al. Central nervous system involvement in Wegener granulomatosis. Medicine 2006; 85: 54-65
55 de Groot K, Schmidt DK, Arlt AC et al. Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol 2001; 58: 1215-1221
56 Nishino H, Rubino FA, DeRemee RA et al. Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 1993; 33: 4-9
57 Faurschou M, Westman K, Rasmussen N et al. Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64: 3472-3477
58 Miloslavsky EM, Specks U, Merkel PA et al. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2014; 66: 3151-3159
59 Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232
60 Specks U, Merkel PA, Seo P et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369: 417-427
61 Guillevin L, Pagnoux C, Karras A et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371: 1771-1780
62 Holle JU, Dubrau C, Herlyn K et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 2012; 71: 327-333
63 Steinbrecher A, Berlit P. Intravenous immunoglobulin treatment in vasculitis and connective tissue disorders. J Neurol 2006; 253 (Suppl. 05) V39-V49
64 Schirmer JH, Wright MN, Vonthein R et al. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology 2015;
65 Greco A, Rizzo MI, De Virgilio A et al. Churg-Strauss syndrome. Autoimm Rev 2015; 14: 341-348
66 Guillevin L, Cohen P, Gayraud M et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine 1999; 78: 26-37
67 Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol 2007; 19: 25-32
68 Comarmond C, Pagnoux C, Khellaf M et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013; 65: 270-281
69 Moosig F, Bremer JP, Hellmich B et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 2013; 72: 1011-1017
70 Ferri C, Mascia MT. Cryoglobulinemic vasculitis. Curr Opin Rheumatol 2006; 18: 54-63
71 Ramos-Casals M, Robles A, Brito-Zeron P et al. Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. Semin Arthritis Rheum 2006; 36: 189-196
72 Casato M, Saadoun D, Marchetti A et al. Central nervous system involvement in hepatitis C virus cryoglobulinemia vasculitis: a multicenter case-control study using magnetic resonance imaging and neuropsychological tests. J Rheumatol 2005; 32: 484-488
73 Berube MD, Blais N, Lanthier S. Neurologic manifestations of Henoch-Schonlein purpura. Handb Clin Neurol 2014; 120: 1101-1111
74 Garzoni L, Vanoni F, Rizzi M et al. Nervous system dysfunction in Henoch-Schonlein syndrome: systematic review of the literature. Rheumatology 2009; 48: 1524-1529
75 Al-Araji A, Kidd DP. Neuro-Behcet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol 2009; 8: 192-204
76 Siva A, Saip S. The spectrum of nervous system involvement in Behcet's syndrome and its differential diagnosis. J Neurol 2009; 256: 513-529
77 Mrabet D, Meddeb N, Ajlani H et al. Cerebral vasculitis in a patient with rheumatoid arthritis. Joint Bone Spine 2007; 74: 201-204
78 Nadeau SE. Neurologic manifestations of connective tissue disease. Neurol Clin 2002; 20: 151-178 vi
79 Chin RL, Latov N. Central nervous system manifestations of rheumatologic diseases. Curr Opin Rheumatol 2005; 17: 91-99
80 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725
81 Orbai AM, Truedsson L, Sturfelt G et al. Anti-C1q antibodies in systemic lupus erythematosus. Lupus 2015; 24: 42-49
82 The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608
83 Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 1988; 23: 380-384
84 Barile-Fabris L, Hernandez-Cabrera MF, Barragan-Garfias JA. Vasculitis in systemic lupus erythematosus. Curr Rheumatol Rep 2014; 16: 440
85 Koerner C, Sommer C, Knauth M et al. Granulomatous cerebral vasculitis in systemic lupus erythematosus during systemic remission of disease. J Neurol 2000; 247: 722-724
86 Rowshani AT, Remans P, Rozemuller A et al. Cerebral vasculitis as a primary manifestation of systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 784-786
87 Bockle BC, Jara D, Aichhorn K et al. Cerebral large vessel vasculitis in systemic lupus erythematosus. Lupus 2014; 23: 1417-1421
88 Romero-Vargas S, Ruiz-Sandoval JL, Barges-Coll J et al. Pathological demonstration of cervical spinal cord inflammatory vasculitis in a patient with spontaneous spinal epidural haematoma associated with systemic lupus erythematosus. Neuropathol Appl Neurobiol 2010; 36: 568-570
89 Ellis SG, Verity MA. Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955–1977. Semin Arthritis Rheum 1979; 8: 212-221
90 Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 2014; 10: 338-347
91 Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 620-625
92 Aringer M, Schneider M. Systemischer Lupus erythematodes – die Standards 2015. Dtsch Med Wochenschr 2014; 139: 1813-1816
93 Massara A, Bonazza S, Castellino G et al. Central nervous system involvement in Sjogren's syndrome: unusual, but not unremarkable – clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology 2010; 49: 1540-1549
94 Soliotis FC, Mavragani CP, Moutsopoulos HM. Central nervous system involvement in Sjogren’s syndrome. Ann Rheum Dis 2004; 63: 616-620
95 Alexander EL. Neurologic disease in Sjogren’s syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. A clinical review and update of immunopathogenesis. Rheum Dis Clin North Am 1993; 19: 869-908
96 Pittock SJ, Lennon VA, de Seze J et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008; 65: 78-83
97 Amaral TN, Peres FA, Lapa AT et al. Neurologic involvement in scleroderma: a systematic review. Seminars in Arthritis Rheum 2013; 43: 335-347
98 Abers MS, Iluonakhamhe EK, Goldsmith CE et al. Central nervous system vasculitis secondary to systemic sclerosis. J Clin Neurosci 2013; 20: 1168-1170
99 Awad AM, Stevenson M. Isolated central nervous system vasculitis associated with antiribonuclear protein antibody. Case Rep Neurol Med 2011; 2011: 495201
100 Said G, Lacroix C, Plante-Bordeneuve V et al. Nerve granulomas and vasculitis in sarcoid peripheral neuropathy: a clinicopathological study of 11 patients. Brain 2002; 125: 264-275
101 Kraemer M, Berlit P. Systemic, secondary and infectious causes for cerebral vasculitis: clinical experience with 16 new European cases. Rheumatol Int 2010; 30: 1471-1476
102 Ferro JM, Oliveira SN, Correia L. Neurologic manifestations of inflammatory bowel diseases. Handb Clin Neurol 2014; 120: 595-605
103 Carmona MA, Jaume Anselmi F, Ramirez Rivera J. Cerebral thrombosis and vasculitis: an uncommon complication of ulcerative colitis. Bol Asoc Med P R 2000; 92: 9-11
104 Ullrich S, Schinke S, Both M et al. Refractory central nervous system vasculitis and gastrocnemius myalgia syndrome in Crohn's disease successfully treated with anti-tumor necrosis factor-alpha antibody. Semin Arthritis Rheum 2009; 38: 337-347
105 Jacobi C, Lenhard T, Meyding-Lamade U. Vasculitis of the nervous system in infectious diseases. Der Nervenarzt 2010; 81: 172-180
106 Katchanov J, Siebert E, Klingebiel R et al. Infectious vasculopathy of intracranial large- and medium-sized vessels in neurological intensive care unit: a clinico-radiological study. Neurocrit Care 2010; 12: 369-374
107 Kastenbauer S, Pfister HW. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Brain 2003; 126: 1015-1025
108 Grahn A, Studahl M. Varicella-zoster virus infections of the central nervous system – Prognosis, diagnostics and treatment. J Infect 2015; 71: 281-293
109 Berlit P, Steinbrecher A. Cerebral vasculitis. Fortschr Neurol Psychiatr 2002; 70: 663-677
110 De Boysson H, Arquizan C, Guillevin L et al. Rituximab for primary angiitis of the central nervous system: report of 2 patients from the French COVAC cohort and review of the literature. J Rheumatol 2013; 40: 2102-2103
111 Salvarani C, Brown Jr. RD, Huston 3rd J et al. Treatment of primary CNS vasculitis with rituximab: case report. Neurology 2014; 82: 1287-1288